Significantly increased antibody response to heterogeneous nuclear ribonucleoproteins in cerebrospinal fluid of multiple sclerosis patients but not in patients with human T-lymphotropic virus type I—associated myelopathy/tropical spastic paraparesis

Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M (2003). Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349: 139–145. Brumwell C, Antolik C, Carson JH, Barbarese E (2002). Intracellular trafficking of hnRNP A2 in oligodendrocytes. Exp Cell Res 279: 310–320. Burd CG, Dreyfuss G (1994). Conserved structures and diversity of functions of RNA-binding proteins. Science 265: 615–621. Couratier P, Yi FH, Preud’homme JL, Clavelou P, White A, Sindou P, Vallat JM, Jauberteau MO (1998). Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis. J Neurol Sci 154: 137–145. Greidinger EL, Gazitt T, Jaimes KF, Hoffman RW (2004). Human T cell clones specific for heterogeneous nuclear ribonucleoprotein A2 autoantigen from connective tissue disease patients assist in autoantibody production. Arthritis Rheum 50: 2216–2222. Hanon E, Goon P, Taylor GP, Hasegawa H, Tanaka Y, Weber JN, Bangham CR (2001). High production of interferon but not interleukin-2 by human T-lymphotropic virus type I-infected peripheral blood mononuclear cells. Blood 98: 721–726. Hassfeld W, Steiner G, Studnicka-Benke A, Skriner K, Graninger W, Fischer I, Smolen JS (1995). Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease and systemic lupus erythematosus. Arthritis Rheum 38: 777–785. Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y, Araki S, Mori M, Nagataki S, Matsukura S, Akamine T, Nakagawa M, Yamamoto I, Osame M (1996). Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 46: 1016–1021. Jacobson S, Shida H, McFarlin DE, Fauci AS, Koenig S (1990). Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 348: 245–248. Jernigan M, Morcos Y, Lee SM, Dohan FC Jr, Raine C, Levin MC (2003). IgG in brain correlates with clinicopathological damage in HTLV-1 associated neurologic disease. Neurology 60: 1320–1327. Jones DA, Yawalkar N, Suh KY, Sadat S, Rich B, Kupper TS (2004). Identification of autoantigens in psoriatic plaques using expression cloning. J Invest Dermatol 123: 93–100. Krecic AM, Swanson MS (1999). hnRNP complexes: composition, structure, and function. Curr Opin Cell Biol 11: 363–371. Kuroda Y, Matsui M, Yukitake M, Kurohara K, Takashima H, Takashima Y, Endo C, Kato A, Mihara F (1995). Assessment of MRI criteria for MS in Japanese MS and HAM/TSP. Neurology 45: 30–33. Levin MC, Krichavsky M, Berk J, Foley S, Rosenfeld M, Dalmau J, Chang G, Posner JB, Jacobson S (1998). Neuronal molecular mimicry in immune-mediated neurologic disease. Ann Neurol 44: 87–98. Levin MC, Lee SM, Kalume F, Morcos Y, Dohan FC Jr, Hasty KA, Callaway JC, Zunt J, Desiderio D, Stuart JM (2002). Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med 8: 509–513. Maggipinto M, Rabiner C, Kidd GJ, Hawkins AJ, Smith R, Barbarese E (2004). Increased expression of the MBP mRNA binding protein hnRNP A2 during oligodendrocyte differentiation. J Neurosci Res 75: 614–623. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001). Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121–127. Meyer O, Tauxe F, Fabregas D, Gabay C, Goycochea M, Haim T, Elias A, Kahn MF (1993). Anti-RA33 antinuclear autoantibody in rheumatoid arthritis and mixed connective tissue disease: comparison with antikeratin and antiperinuclear antibodies, Clin Exp Rheumatol 11: 473–478. Munro TP, Magee RJ, Kidd GJ, Carson JH, Barbarese E, Smith LM, Smith R (1999). Mutational analysis of a nuclear ribonucleoprotein A2 response element for RNA trafficking. J Biol Chem 274: 34389–34395. Nagai M, Jacobson S (2001). Immunopathogenesisi of human T cell lymphotropic virus type I-associated myelopathy. Curr Opin Neurol 14: 381–386. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000). Multiple sclerosis. N Engl J Med 343: 938–952. Osame M (1990). Review of WHO Kagoshima Meeting and Diagnostic guidelines for HAM/TSP. In: Human retrovirology: HTLV, 1st ed. Blattner WA (ed). New York: Raven Press, pp 191–197. Osame M (2002). Pathological mechanisms of human T-cell lymphotropic virus type I-associated myelopathy (HAM/TSP). J NeuroVirol 8: 359–364. Steiner G, Hartmuth K, Skriner K, Maurer-Fogy I, Sinski A, Thalmann E, Hassfeld W, Barta A, Smolen JS (1992). Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest 90: 1061–1066. Steinman L (1996). Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85: 299–302. Sueoka E, Sueoka N, Goto Y, Matsuyama S, Nishimura H, Sato M, Fujimura S, Chiba H, Fujiki H (2001). Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia. Cancer Res 61: 1896–1902. Sueoka E, Yukitake M, Iwanaga K, Sueoka N, Aihara T, Kuroda Y (2004). Autoantibodies against heterogeneous nuclear ribonucleoprotein B1 in CSF of MS patients. Ann Neurol 56: 778–786.